company background image
AIKI

AIkido Pharma NasdaqCM:AIKI Stock Report

Last Price

US$6.30

Market Cap

US$30.8m

7D

3.4%

1Y

-52.5%

Updated

15 Aug, 2022

Data

Company Financials +
AIKI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AIKI Stock Overview

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics.

AIkido Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AIkido Pharma
Historical stock prices
Current Share PriceUS$6.30
52 Week HighUS$16.58
52 Week LowUS$4.30
Beta1.37
1 Month Change0.31%
3 Month Change13.16%
1 Year Change-52.50%
3 Year Change-82.68%
5 Year Change-94.45%
Change since IPO-100.00%

Recent News & Updates

Aug 09

Alkido Pharma shareholders proposes to acquire company at $8/share in cash

Alkido Pharma's (NASDAQ:AIKI) significant stockholder Shalom Auerbach, who owns ~3.8% of its stock, announced that he has sent a letter proposing to acquire the company for $8/share in cash. This proposal to buy AIKI represents a 31% premium to the company’s most recent closing share price on Aug.8, 2022. It will provide substantial and immediate cash value for stockholders. The shareholder indicates that he will not hold this proposal open indefinitely and it is critical that the company meets with him by no later than Aug.23, 2022.

Shareholder Returns

AIKIUS BiotechsUS Market
7D3.4%1.4%3.6%
1Y-52.5%-19.6%-9.6%

Return vs Industry: AIKI underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: AIKI underperformed the US Market which returned -10.2% over the past year.

Price Volatility

Is AIKI's price volatile compared to industry and market?
AIKI volatility
AIKI Average Weekly Movement7.1%
Biotechs Industry Average Movement12.6%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: AIKI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: AIKI's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19675Anthony Hayeshttps://www.aikidopharma.com

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company’s pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

AIkido Pharma Fundamentals Summary

How do AIkido Pharma's earnings and revenue compare to its market cap?
AIKI fundamental statistics
Market CapUS$30.77m
Earnings (TTM)-US$14.58m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AIKI income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$14.58m
Earnings-US$14.58m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.91
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did AIKI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is AIKI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AIKI?

Other financial metrics that can be useful for relative valuation.

AIKI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does AIKI's PB Ratio compare to its peers?

AIKI PB Ratio vs Peers
The above table shows the PB ratio for AIKI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.9x
AGTC Applied Genetic Technologies
0.7x6.0%US$32.4m
ENZN Enzon Pharmaceuticals
9xn/aUS$29.7m
CRBP Corbus Pharmaceuticals Holdings
0.7x21.6%US$32.2m
IDRA Idera Pharmaceuticals
1.1xn/aUS$24.3m
AIKI AIkido Pharma
0.4x-10.6%US$30.8m

Price-To-Book vs Peers: AIKI is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (2.9x).


Price to Earnings Ratio vs Industry

How does AIKI's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: AIKI is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (1.9x)


Price to Book Ratio vs Fair Ratio

What is AIKI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AIKI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AIKI's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of AIKI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AIKI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AIKI's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is AIkido Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-10.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AIKI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AIKI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AIKI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AIKI's revenue is forecast to grow faster than the US market.

High Growth Revenue: AIKI is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AIKI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has AIkido Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-26.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AIKI is currently unprofitable.

Growing Profit Margin: AIKI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AIKI is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.

Accelerating Growth: Unable to compare AIKI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AIKI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: AIKI has a negative Return on Equity (-11.97%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is AIkido Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AIKI's short term assets ($61.6M) exceed its short term liabilities ($829.0K).

Long Term Liabilities: AIKI has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: AIKI is debt free.

Reducing Debt: AIKI has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AIKI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AIKI has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 32.1% each year


Discover healthy companies

Dividend

What is AIkido Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AIKI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AIKI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AIKI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AIKI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AIKI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average board tenure


CEO

Anthony Hayes (54 yo)

8.92yrs

Tenure

US$460,000

Compensation

Mr. Anthony C. Hayes, Esq. has been the Chief Executive Officer and Principal Accounting Officer of Alkido Pharma Inc. (fka AIkido Pharma Inc. (formerly known as Spherix Incorporated)) since September 10,...


CEO Compensation Analysis

Compensation vs Market: Anthony's total compensation ($USD460.00K) is below average for companies of similar size in the US market ($USD759.98K).

Compensation vs Earnings: Anthony's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: AIKI's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AIkido Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AIkido Pharma Inc.
  • Ticker: AIKI
  • Exchange: NasdaqCM
  • Founded: 1967
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$30.774m
  • Shares outstanding: 5.00m
  • Website: https://www.aikidopharma.com

Number of Employees


Location

  • AIkido Pharma Inc.
  • One Rockefeller Plaza
  • 11th Floor
  • New York
  • New York
  • 10020
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/15 00:00
End of Day Share Price2022/08/15 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.